Company · Private
Vandria
Swiss biotech developing small molecules that induce mitophagy — the selective clearance of damaged mitochondria — led by VNA-318 for CNS and muscle disorders.
Listing
Private
Ticker
—
Headquarters
Lausanne, Switzerland
Founded
—
Technology
Mitophagy-inducing small molecules
Category
Longevity thesis
Mitochondrial quality control declines with age; pharmacologically restoring mitophagy could improve cellular energy homeostasis across tissues.
Programmes
- VNA-318Phase 1
CNS and muscle disorders (mitophagy)
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.